Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc covers the period ending February 2015. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding the vesting of conditional share awards under the GlaxoSmithKline Share Value Plan (SVP).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on equity compensation events. The fair market values at the point of vesting on February 17, 2015, were:
- Ordinary Share: £15.475
- American Depositary Share (ADS): US$47.71
Material Changes
The restricted period for the 2012 SVP awards, which commenced on August 22, 2012, has ended, resulting in the vesting of awards on February 17, 2015. The specific vesting details for PDMRs are as follows:
| Name of PDMR | Number of Ordinary Shares Vested | Number of ADS Vested |
|---|---|---|
| Mr R Connor | 17,920 | Not specified |
| Mr N Hirons | 5,740 | Not specified |
| Mrs V Whyte | 13,070 | Not specified |
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total number of shares vested for each named PDMR against internal company records.
- Confirm the fair market value of the Ordinary Share (£15.475) and ADS (US$47.71) on the vesting date of February 17, 2015.
- Note that the filing does not disclose the number of ADSs vested, only the number of Ordinary Shares.
- Confirm that the vesting was conditional on continued employment with the GlaxoSmithKline group.